Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer

BACKGROUND: Approximately 20-25% of ovarian cancers are attributable to germline or somatic BRCA1/2 mutations, resulting in defects in the homologous recombination pathway. Inactivation of these genes can also be mediated by epigenetic changes, e.g., hypermethylation of CpG islands in the promoter r...

Descripción completa

Detalles Bibliográficos
Autores principales: Prieske, Katharina, Prieske, Stefan, Joosse, Simon A., Trillsch, Fabian, Grimm, Donata, Burandt, Eike, Mahner, Sven, Schmalfeldt, Barbara, Milde-Langosch, Karin, Oliveira-Ferrer, Leticia, Woelber, Linn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669950/
https://www.ncbi.nlm.nih.gov/pubmed/29137324
http://dx.doi.org/10.18632/oncotarget.20945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669950/
https://www.ncbi.nlm.nih.gov/pubmed/29137324
http://dx.doi.org/10.18632/oncotarget.20945

Ejemplares similares